Select a State

Global health R&D delivers for Wisconsin

US government investment in global health R&D has delivered

$62.0 million
to Wisconsin research institutions
800+ new jobs
for Wisconsin

Neglected diseases in Wisconsin

Chikungunya cases
31
Dengue cases
54
HIV diagnoses
2,134
Malaria cases
105
Tuberculosis cases
538
West Nile cases
120
Zika cases
64

Wisconsin's top USG-funded global health R&D institutions

University of Wisconsin
$56.4 million
Medical College of Wisconsin
$5.2 million
Concordia University Wisconsin
$396 thousand

Wisconsin industry in global health R&D

GoDX
Location(s):
Madison
IoGenetics
Location(s):
Madison
Lucigen Corporation
Location(s):
Middleton
Luminex
Location(s):
Madison
Salus Discovery
Location(s):
Madison

Wisconsin's top areas of global health R&D by USG funding

40.9%
HIV/AIDS
22.0%
Tuberculosis
2.4%
Diarrheal diseases
3.7%
Ebola/viral hemorrhagic fevers
6.0%
Salmonella infections
19.1%
Neglected tropical diseases
Dengue
Helminths
Kinetoplastids
3.2%
Other
Bacteria pneumonia & meningitis
Non-allocable

Global health R&D at work in Wisconsin

Aiming to stop the devastation of Zika, researchers at the University of Wisconsin (UW) at Madison are testing if mosquitoes—artificially infected with a bacterium called Wolbachia, found in 40 percent of the world’s insects—could be released into the wild to control Zika. Scientists from UW-Madison have already released Wolbachia-infected mosquitoes into countries with dengue virus, a related infection, to study the effect. In the lab, mosquitoes with Wolbachia have proven less capable of harboring Zika, indicating the bacterium could be used as a biological control mechanism. Another UW-Madison study found that monkeys infected with Zika are protected from future infection. These findings suggest that a vaccine against Zika should be effective.

Footnotes